Physician profile
Majdy Albahhar
NPI 1013163211
$9,609.20
in general payments reported to CMS, 2019-2025
43 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 91% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $671 · 2021: $666 · 2022: $1,129 · 2023: $1,408 · 2024: $2,507 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,229 · Long Term Medical Supply Or Device Loan: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,229.15 |
| Long Term Medical Supply Or Device Loan | $139.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,564.64 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,140.33 | 2019-2025 | Tremfya, Stelara, Remicade |
| Sun Pharmaceutical Industries INC. | $709.59 | 2019-2025 | Winlevi, Blu-U, Ilumya |
| Leo Pharma INC. | $523.05 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $467.41 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $461.83 | 2023-2024 | Vtama |
| Pfizer INC. | $446.28 | 2019-2025 | |
| Kerecis Limited | $382.98 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Novartis Pharmaceuticals Corporation | $381.52 | 2021-2025 | |
| Galderma Laboratories, L.P. | $324.09 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $301.13 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $295.40 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $245.43 | 2019-2025 | |
| Amgen INC. | $243.38 | 2020-2025 | Otezla, Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $237.52 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majdy Albahhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.